Platelet-activating factor (PAF), a mediator of proatherosclerotic inflammatory processes, is also implicated in endothelial dysfunction during human immunodeficiency virus (HIV) infection. We examined PAF metabolism in blood of naive male patients, 8 with early HIV infection (group A) and 17 just before treatment initiation (group B), versus 18 healthy age-matched males (group C). Statistical analysis was performed with 1-way analysis of variance (ANOVA) criterion and Pearson r test. Higher PAF biosynthesis in patients’ leukocytes versus group C was accompanied by an increase in lipoprotein-associated phospholipase A2 (Lp-PLA2) activity that degrades PAF. Moreover, PAF synthesis was higher and Lp-PLA2 activity was lower in group B compared to group A. Lipoprotein-associated phospholipase A2 was positively correlated with viral load and negatively correlated with CD4 cell counts in group B. The activities of PAF-basic biosynthetic enzymes in patients’ leukocytes were also negatively correlated with CD4 cell counts. The observed continuous increase in PAF biosynthesis during HIV infection progress seems to amplify the risk of AIDS manifestations and/or cardiovascular complications in HIV-infected patients, while a subsequent increase in Lp-PLA2 activity seems to be a host response.
DemopoulosCAPinckardRNHanahanDJ.Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphoryl-choline as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979;254(19):9355–9358.
2.
ZimmermanGAMcIntyreTMPrescottSMStafforiniDM.The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002;30(5 suppl):S294–S301.
3.
StafforiniDMMcIntyreTMZimmermanGAPrescottSM.Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci. 2003;40(6):643–672.
4.
SnyderF.Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta. 1995;1254(3):231–249.
5.
FrancescangeliEBoilaAGoracciG.Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex. Neurochem Res. 2000;25(5):705–713.
6.
SnyderF.CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Biochim Biophys Acta. 1997;1348(1-2):111–116.
7.
TsouprasABFragopoulouENomikosTIatrouCAntonopoulouSDemopoulosCA.Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDT-insensitive cholinephosphotransferase, of human mesangial cells. Mediators Inflamm. 2007;2007:27683.
8.
DetopoulouPNomikosTFragopoulouE. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. Clin Biochem. 2009;42(1-2):44–49.
9.
ImagawaMMimataHTakahashiSINakagawaMNomuraYOgataJ.Modulation of platelet-activating factor synthesis by recombinant interferon-α in human renal cell carcinoma. Urol Int. 1996;57(1):11–16.
10.
GimenezRAguilarJ.Cytidine (5-) diphosphocholine induced decrease in cerebral platelet activating factor is due to inactivation of its synthesizing enzyme cholinephosphotransferase in aged rats. Neurosci Lett. 2001;299(3):209–212.
11.
KarasawaK.Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim Biophys Acta. 2006;1761(11):1359–1372.
12.
MontrucchioGAlloattiGCamussiG.Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000;80(4):1669–1699.
13.
DemopoulosCAKarantonisHCAntonopoulouS.Platelet activating factor—a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003;105(11):705–716.
14.
López-NovoaJM.Potential role of platelet activating factor in acute renal failure. Kidney Int. 1999;55(5):1672–1682.
15.
McManusLMPinckardRN.PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med. 2000;11(2):240–258.
16.
Kasperska-ZajacABrzozaZRogalaB.Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov. 2008;2(1):72–76.
17.
NathanNDenizotYHucMC. Elevated levels of paf-acether in blood of patients with type 1 diabetes mellitus. Diabete Metab. 1992;18(1):59–62.
18.
TsouprasABIatrouCFrangiaCDemopoulosCA.The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets. 2009;9(4):390–399.
TsouprasABChiniMTsogasN. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?. AIDS Res Hum Retroviruses. 2008;24(8):1079–1086.
21.
TsantilaNTsouprasABFragopoulouEAntonopoulouSIatrouCDemopoulosCA.In vitro and in vivo effects of statins on platelet activating factor and its metabolism. Angiology. 2011;62(3):209–218.
22.
PerrySWHamiltonJATjoelkerLW. Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J Biol Chem. 1998;273(28):17660–17664.
23.
BianconeLCantaluppiVBoccellinoM. Motility induced by human immunodeficiency virus-1 tat on Kaposi’s sarcoma cells requires platelet-activating factor synthesis. Am J Pathol. 1999;155(5):1731–1739.
24.
DoublierSZennaroCSpatolaT. HIV-1 tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS. 2007;21(4):423–432.
25.
MartinMSerradjiNDereuddre-BosquetN. PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages. Antimicrob Agents Chemother. 2000;44(11):3150–3154.
26.
BradfordMM.A rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254.
27.
BlighEGDyerWJ.A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911–917.
28.
AntonopoulouSDemopoulosCAIatrouCMoustakasGZirogiannisP.Platelet-activating factor acetylhydrolase (PAF-AH) in human kidney. Int J Biochem. 1994;26(9):1157–1162.
29.
CurrierJS.Update on cardiovascular complications in HIV infection. Top HIV Med. 2009;17(3):98–103.
30.
MalvestuttoCDAbergJA.Coronary heart disease in people infected with HIV. Cleve Clin J Med. 2010;77(8):547–56.
31.
ParaskevasKIKatsikiNTzovarasAAKoupidisSAMikhailidisDP.Peripheral arterial disease and HIV-positive patients. Angiology. 2011;62(1):7–9.
32.
BhaskaranKHamoudaOSannesM. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51–59.
33.
CockerhamLScherzerRZolopaARimlandDLewisCEBacchettiP. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr. 2010;53(1):102–6.
34.
BernatchezPNWinsteadMVDennisEASiroisMG.VEGF stimulation of endothelial cell PAF synthesis is mediated by group V 14 kDa secretory phospholipase A2. Br J Pharmacol. 2001;134(1):197–205.
35.
FrancescangeliEDomanska-JanikKGoracciG.Relative contribution of the de novo and remodelling pathways to the synthesis of platelet-activating factor in brain areas and during ischemia. J Lipid Mediat Cell Signal. 1996;14(1-3):89–98.
36.
BakerRRChangHY.The potential for platelet-activating factor synthesis in brain: properties of cholinephosphotransferase and 1-alkyl-sn-glycero-3-phosphate acetyltransferase in microsomal fractions of immature rabbit cerebral cortex. Biochim Biophys Acta. 1993;1170(2):157–164.
37.
FrancescangeliEBoilaAGoracciG.Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex. Neurochem Res. 2000;25(5):705–713.
38.
IbeBOPortugalAMUsha RajJ.Metabolism of platelet activating factor by intrapulmonary vascular smooth muscle cells. Effect of oxygen on phospholipase A2 protein expression and activities of acetyl-CoA acetyltransferase and cholinephosphotransferase. Mol Genet Metab. 2002;77(3):237–248.
39.
FrancescangeliEGrassiSPettorossiVEGoracciG.Activation of PAF-synthesizing enzymes in rat brain stem slices after LTP induction in the medial vestibular nuclei. Neurochem Res. 2002;27(11):1465–1471.
40.
KhovidhunkitWMemonRAShigenagaJK. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism. 1999;48(12):1524–1531.
41.
GrunfeldC.Dyslipidemia and its treatment in HIV infection. Top HIV Med. 2010;18(3):112–118.
42.
ScanuAMEdelsteinC.HDL: bridging past and present with a look at the future. FASEB J. 2008;22(12):4044–4054.
43.
SquintoSPBraquetPBlockALBazanNG.Platelet-activating factor activates HIV promoter in transfected SH-SY5Y neuroblastoma cells and MOLT-4 T lymphocytes. J Mol Neurosci. 1990;2(2):79–84.
44.
LimaRGMoreiraLPaes-LemeJ. Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor. AIDS Res Hum Retroviruses. 2006;22(8):763–769.
45.
KuceraLSIyerNLeakeE. Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation. AIDS Res Hum Retroviruses. 1990;6(4):491–501.
46.
TsouprasABChiniMTsogasN. Effects of highly active antiretroviral therapy (HAART) on platelet activating factor (PAF) metabolism in HIV-infected patients: in vivo results. J Int AIDS Soc. 2008;11(suppl 1):P105. doi:10.1186/1758-2652-11-S1-P105
